318 related articles for article (PubMed ID: 32749654)
41. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy.
Bahn RS; Dutton CM; Natt N; Joba W; Spitzweg C; Heufelder AE
J Clin Endocrinol Metab; 1998 Mar; 83(3):998-1002. PubMed ID: 9506762
[TBL] [Abstract][Full Text] [Related]
42. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy.
Hou J; Tang Y; Chen Y; Chen D
Front Cell Infect Microbiol; 2021; 11():739707. PubMed ID: 35004341
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
44. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N
Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425
[TBL] [Abstract][Full Text] [Related]
45. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.
Cui X; Wang F; Liu C
Front Immunol; 2023; 14():1062045. PubMed ID: 36742308
[TBL] [Abstract][Full Text] [Related]
46. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
[TBL] [Abstract][Full Text] [Related]
47. The role and molecular mechanism of gut microbiota in Graves' orbitopathy.
Li Y; Luo B; Tong B; Xie Z; Cao J; Bai X; Peng Y; Wu Y; Wang W; Qi X
J Endocrinol Invest; 2023 Feb; 46(2):305-317. PubMed ID: 35986869
[TBL] [Abstract][Full Text] [Related]
48. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
49. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
50. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
51. Cre-loxP System-Based Mouse Model for Investigating Graves' Disease and Associated Orbitopathy.
Bao Y; Kim D; Cho YH; Ku CR; Yoon JS; Lee EJ
Thyroid; 2023 Nov; 33(11):1358-1367. PubMed ID: 37624749
[No Abstract] [Full Text] [Related]
52. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
Khoo TK; Bahn RS
Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
[TBL] [Abstract][Full Text] [Related]
53. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
54. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies.
Diana T; Wüster C; Kanitz M; Kahaly GJ
J Endocrinol Invest; 2016 Oct; 39(10):1159-65. PubMed ID: 27197966
[TBL] [Abstract][Full Text] [Related]
55. Association between polymorphisms in the TSHR gene and Graves' orbitopathy.
Jurecka-Lubieniecka B; Ploski R; Kula D; Szymanski K; Bednarczuk T; Ambroziak U; Hasse-Lazar K; Hyla-Klekot L; Tukiendorf A; Kolosza Z; Jarzab B
PLoS One; 2014; 9(7):e102653. PubMed ID: 25061884
[TBL] [Abstract][Full Text] [Related]
56. Association of clinical course with thyroid-stimulating immunoglobulin in Graves' ophthalmopathy in Mongolians.
Bayarmunkh O; Ganbold C; Das S; Davaatseren U; Minjuurdorj NE; Jav S
PLoS One; 2022; 17(11):e0277055. PubMed ID: 36395261
[TBL] [Abstract][Full Text] [Related]
57. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells.
Kamijo K; Murayama H; Uzu T; Togashi K; Kahaly GJ
Thyroid; 2010 Aug; 20(8):851-6. PubMed ID: 20615137
[TBL] [Abstract][Full Text] [Related]
58. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A
Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515
[TBL] [Abstract][Full Text] [Related]
59. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
[TBL] [Abstract][Full Text] [Related]
60. Expression of Endogenous Putative TSH Binding Protein in Orbit.
Draman MS; Grennan-Jones F; Taylor P; Muller I; Evans S; Haridas A; Morris DS; Rees DA; Lane C; Dayan C; Zhang L; Ludgate M
Curr Issues Mol Biol; 2021 Oct; 43(3):1794-1804. PubMed ID: 34889904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
